+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Malignant Mesothelioma Market by Drug Type, Treatment Type, Route of Administration, Distribution - Global Forecast 2025-2030- Product Image
Malignant Mesothelioma Market by Drug Type, Treatment Type, Route of Administration, Distribution - Global Forecast 2025-2030- Product Image
Sale

Malignant Mesothelioma Market by Drug Type, Treatment Type, Route of Administration, Distribution - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 189 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5889052
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Malignant Mesothelioma Market grew from USD 772.67 million in 2023 to USD 834.43 million in 2024. It is expected to continue growing at a CAGR of 8.26%, reaching USD 1.34 billion by 2030.

Malignant Mesothelioma is a rare yet aggressive cancer primarily affecting the linings of the lungs or abdomen, often linked to asbestos exposure. In the market research context, the scope includes not just the prevalence and demographics of the disease but also the pharmaceutical and therapeutic interventions, diagnostics, and supportive care associated with its management. The necessity for advancements in this area stems from the disease’s high morbidity and mortality rates, underscoring the need for better diagnosis, treatment options, and palliative care. The application scope encompasses various stakeholders, including hospitals, specialty clinics, and even home healthcare providers, as they battle the complexities of delivery and accessibility of care. End-use scope extends into pharmaceuticals, biotechnology firms, and research institutes heavily involved in R&D to innovate therapies like immunotherapies and multimodal treatments.

Market growth is driven by increasing awareness, the development of novel therapeutics, and significant investments into research by both government and private entities. Emerging opportunities lie in precision medicine approaches, personalized therapies, and diagnostic advancements leveraging AI and machine learning to improve early detection. However, growth is hampered by the rarity of the disease, leading to less commercial incentive for drug companies, as well as regulatory challenges. High treatment costs and limited insurance coverage further strain market expansion. Best areas for innovation include biomarker research for early diagnosis, reduction of side effects in chemotherapy, and more comprehensive patient-centric approaches that merge existing therapeutic frameworks with novel innovations.

To thrive, businesses should invest in collaborations with biotech firms focusing on rare diseases and pursue strategic alliances for technology integration in diagnostics. The nature of the market is highly fragmented, competitive, and research-intensive, requiring agile adaptation to emerging scientific breakthroughs and regulatory landscapes. Establishing platforms for patient advocacy and awareness can also foster improved market penetration, ensuring competitive advantage and sustained growth.

Understanding Market Dynamics in the Malignant Mesothelioma Market

The Malignant Mesothelioma Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising incidence of malignant mesothelioma worldwide
    • Increase in the number of clinical trials for the treatment of malignant mesothelioma
    • Use of diagnostic and prognostic biomarkers for malignant mesothelioma treatment
  • Market Restraints
    • High cost of malignant mesothelioma surgical treatment
  • Market Opportunities
    • Introduction of novel therapies for the treatment of malignant mesothelioma
    • Favorable funding landscape for research on malignant mesothelioma
  • Market Challenges
    • Adverse effects associated with the treatment of malignant mesothelioma

Exploring Porter’s Five Forces for the Malignant Mesothelioma Market

Porter’s Five Forces framework further strengthens the insights of the Malignant Mesothelioma Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Malignant Mesothelioma Market

External macro-environmental factors deeply influence the performance of the Malignant Mesothelioma Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Malignant Mesothelioma Market

The Malignant Mesothelioma Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Malignant Mesothelioma Market

The Malignant Mesothelioma Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Malignant Mesothelioma Market

The Malignant Mesothelioma Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Malignant Mesothelioma Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Advanz Pharma Corp., Argenx SE, AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddy's Laboratories, Eisai Co., Ltd., Eli Lilly and Company, Emcure Pharmaceuticals Limited, F. Hoffmann-La Roche Ltd., Fresenius Kabi AG, Karyopharm Therapeutics Inc., Merck & Co., Inc., Mylan N.V., Nichi-Iko Pharmaceutical Co., Ltd., Novartis AG, Novocure GmbH, Ono Pharmaceutical Co. Ltd., Pfizer Inc., Polaris Pharmaceuticals, Inc., Sanofi S.A., Sun Pharmaceuticals Industries Ltd., and Wellona Pharma.

Market Segmentation & Coverage

This research report categorizes the Malignant Mesothelioma Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Drug Type
    • Carboplatin
    • Cisplatin
    • Gemcitabine
    • Pemetrexed
    • Vinorelbine
  • Treatment Type
    • Chemotherapy
      • Local Chemotherapy
      • Systemic Chemotherapy
    • Immunotherapy
    • Targeted therapy
  • Route of Administration
    • Oral
    • Parenteral
  • Distribution
    • Hospitals Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidence of malignant mesothelioma worldwide
5.1.1.2. Increase in the number of clinical trials for the treatment of malignant mesothelioma
5.1.1.3. Use of diagnostic and prognostic biomarkers for malignant mesothelioma treatment
5.1.2. Restraints
5.1.2.1. High cost of malignant mesothelioma surgical treatment
5.1.3. Opportunities
5.1.3.1. Introduction of novel therapies for the treatment of malignant mesothelioma
5.1.3.2. Favorable funding landscape for research on malignant mesothelioma
5.1.4. Challenges
5.1.4.1. Adverse effects associated with the treatment of malignant mesothelioma
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Malignant Mesothelioma Market, by Drug Type
6.1. Introduction
6.2. Carboplatin
6.3. Cisplatin
6.4. Gemcitabine
6.5. Pemetrexed
6.6. Vinorelbine
7. Malignant Mesothelioma Market, by Treatment Type
7.1. Introduction
7.2. Chemotherapy
7.2.1. Local Chemotherapy
7.2.2. Systemic Chemotherapy
7.3. Immunotherapy
7.4. Targeted therapy
8. Malignant Mesothelioma Market, by Route of Administration
8.1. Introduction
8.2. Oral
8.3. Parenteral
9. Malignant Mesothelioma Market, by Distribution
9.1. Introduction
9.2. Hospitals Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
10. Americas Malignant Mesothelioma Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Malignant Mesothelioma Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Malignant Mesothelioma Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. MALIGNANT MESOTHELIOMA MARKET RESEARCH PROCESS
FIGURE 2. MALIGNANT MESOTHELIOMA MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
FIGURE 13. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. MALIGNANT MESOTHELIOMA MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. MALIGNANT MESOTHELIOMA MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. MALIGNANT MESOTHELIOMA MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. MALIGNANT MESOTHELIOMA MARKET DYNAMICS
TABLE 7. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CARBOPLATIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CISPLATIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY GEMCITABINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PEMETREXED, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY VINORELBINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY LOCAL CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SYSTEMIC CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 43. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 44. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 45. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 46. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 47. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 48. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 49. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 50. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 51. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 59. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 60. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 65. AUSTRALIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 66. AUSTRALIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 67. AUSTRALIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 68. AUSTRALIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. AUSTRALIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 70. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 71. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 72. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 73. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 75. INDIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 76. INDIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 77. INDIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 78. INDIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 79. INDIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 80. INDONESIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 81. INDONESIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 82. INDONESIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 83. INDONESIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. INDONESIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 85. JAPAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 86. JAPAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 87. JAPAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 88. JAPAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. JAPAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 90. MALAYSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 91. MALAYSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 92. MALAYSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 93. MALAYSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. MALAYSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 95. PHILIPPINES MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 96. PHILIPPINES MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 97. PHILIPPINES MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 98. PHILIPPINES MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. PHILIPPINES MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 100. SINGAPORE MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 101. SINGAPORE MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 102. SINGAPORE MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 103. SINGAPORE MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 104. SINGAPORE MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 105. SOUTH KOREA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 106. SOUTH KOREA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 107. SOUTH KOREA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 108. SOUTH KOREA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. SOUTH KOREA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 110. TAIWAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 111. TAIWAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 112. TAIWAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 113. TAIWAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. TAIWAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 115. THAILAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 116. THAILAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 117. THAILAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 118. THAILAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. THAILAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 120. VIETNAM MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 121. VIETNAM MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 122. VIETNAM MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 123. VIETNAM MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. VIETNAM MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 131. DENMARK MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 132. DENMARK MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 133. DENMARK MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 134. DENMARK MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. DENMARK MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 136. EGYPT MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 137. EGYPT MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 138. EGYPT MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 139. EGYPT MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. EGYPT MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 141. FINLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 142. FINLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 143. FINLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 144. FINLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. FINLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 146. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 147. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 148. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 149. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 150. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 151. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 152. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 153. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 154. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 156. ISRAEL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 157. ISRAEL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 158. ISRAEL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 159. ISRAEL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. ISRAEL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 161. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 162. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 163. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 164. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 166. NETHERLANDS MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 167. NETHERLANDS MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 169. NETHERLANDS MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 171. NIGERIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 172. NIGERIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 173. NIGERIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 174. NIGERIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. NIGERIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 176. NORWAY MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 177. NORWAY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 178. NORWAY MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 179. NORWAY MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. NORWAY MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 181. POLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 182. POLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 183. POLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 184. POLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. POLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 186. QATAR MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 187. QATAR MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 188. QATAR MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 189. QATAR MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. QATAR MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 206. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 207. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 208. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 209. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 211. SWEDEN MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 212. SWEDEN MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 214. SWEDEN MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 215. SWEDEN MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 216. SWITZERLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 217. SWITZERLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 218. SWITZERLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 219. SWITZERLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 221. TURKEY MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 222. TURKEY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 223. TURKEY MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 224. TURKEY MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. TURKEY MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 232. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 236. MALIGNANT MESOTHELIOMA MARKET SHARE, BY KEY PLAYER, 2023
TABLE 237. MALIGNANT MESOTHELIOMA MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Malignant Mesothelioma Market, which are profiled in this report, include:
  • AbbVie Inc.
  • Advanz Pharma Corp.
  • Argenx SE
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Emcure Pharmaceuticals Limited
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • Karyopharm Therapeutics Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Nichi-Iko Pharmaceutical Co., Ltd.
  • Novartis AG
  • Novocure GmbH
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Polaris Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Sun Pharmaceuticals Industries Ltd.
  • Wellona Pharma

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages189
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 834.43 Million
Forecasted Market Value ( USD ) by 2030 $ 1340 Million
Compound Annual Growth Rate8.2%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Malignant Pleural Mesothelioma Market (2024 Edition): Analysis By Drug Type, By Route of Administration, By Distribution Channel, By Region, By Country: Market Insights and Forecast (2020-2030) - Product Image

Malignant Pleural Mesothelioma Market (2024 Edition): Analysis By Drug Type, By Route of Administration, By Distribution Channel, By Region, By Country: Market Insights and Forecast (2020-2030)

  • Report
  • 259 Pages
  • Global
From
Malignant Mesothelioma Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Malignant Mesothelioma Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 223 Pages
  • Global
Malignant Pleural Mesothelioma Market Report and Forecast 2024-2032 - Product Image

Malignant Pleural Mesothelioma Market Report and Forecast 2024-2032

  • Report
  • 160 Pages
  • Global
From
Malignant Mesothelioma - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Malignant Mesothelioma - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Malignant Pleural Mesothelioma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Malignant Pleural Mesothelioma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 137 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.